Paragon Bioservices Wins CMO Leadership Awards
Life Science Leader Magazine Recognizes Paragon Fifth Year in a Row
Baltimore, MD, February 9, 2016/PR Newswire/ – Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today that it has received CMO Leadership Awards for 2016. Paragon received the awards in all five of the core categories and for both the small pharma and overall groups.
Paragon’s focus is the development and manufacturing of biopharmaceuticals—including the production and purification of recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon’s cGMP facilities include microbial and mammalian suites, aseptic fill-finish and fully-segregated virus facilities. Paragon functions as a translational bridge—from the research bench through manufacturing of finished drug product for Phase I/II clinical trials. Paragon’s aim is to build strong development and manufacturing partnerships with biopharmaceutical clients, focusing on transformative technologies, including oncology immunotherapies (CAR-T cell therapies and oncolytic viruses), new generation vaccines (VLPs) and gene therapies (AAV).
Peter Buzy, President of Paragon Bioservices, commented that credit for this outstanding recognition goes to all of Paragon’s hard working scientists, engineers, quality systems personnel and project managers. “We are honored by this acknowledgement from our clients and hope that it reflects our dedication to their programs and passion for the science,” said Mr. Buzy.
“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science Leader magazine and OutsourcedPharma.com. “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 5 critical categories of capabilities, compatibility, expertise, quality, and reliability. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”
About Paragon Bioservices, Inc.
Paragon Bioservices is a private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon’s cGMP facilities include microbial and mammalian suites, fill-finish and fully-segregated virus facilities.
Kevin Sly, SVP Marketing & Commercial Strategy
PH (410) 975-4053